Clinical Trial Update: Dinaciclib and Epirubicin Hydrochloride in Treating Patients With Metastatic Triple-Negative Breast Cancer [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the combination of dinaciclib and epirubicin hydrochloride in metastatic triple-negative breast cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Estrogen Receptor Negative Breast Cancer
• Progesterone Receptor-negative Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Dinaciclib (dinaciclib)
• ELLENCE (Epirubicin hydrochloride)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Estrogen Receptor Negative, HER2/Neu Negative | Phase 1 | Status: COMPLETED